Townsquare Capital LLC Sells 13,141 Shares of Novo Nordisk A/S $NVO

Townsquare Capital LLC trimmed its stake in Novo Nordisk A/S (NYSE:NVO) by 38.5% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 21,000 shares of the company’s stock after selling 13,141 shares during the quarter. Townsquare Capital LLC’s holdings in Novo Nordisk A/S were worth $1,165,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Werba Rubin Papier Wealth Management increased its stake in shares of Novo Nordisk A/S by 4.1% during the 2nd quarter. Werba Rubin Papier Wealth Management now owns 4,378 shares of the company’s stock worth $302,000 after purchasing an additional 173 shares during the last quarter. Beacon Financial Group increased its position in Novo Nordisk A/S by 4.3% during the third quarter. Beacon Financial Group now owns 4,307 shares of the company’s stock worth $239,000 after buying an additional 178 shares during the last quarter. Copeland Capital Management LLC increased its position in Novo Nordisk A/S by 47.3% during the second quarter. Copeland Capital Management LLC now owns 579 shares of the company’s stock worth $40,000 after buying an additional 186 shares during the last quarter. Revolve Wealth Partners LLC raised its stake in Novo Nordisk A/S by 8.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after buying an additional 200 shares during the period. Finally, Kavar Capital Partners Group LLC lifted its position in shares of Novo Nordisk A/S by 0.6% in the third quarter. Kavar Capital Partners Group LLC now owns 32,631 shares of the company’s stock valued at $1,811,000 after buying an additional 200 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Very strong launch demand for Wegovy pill: IQVIA data show the pill tracked over 26,000 U.S. prescriptions in its second full week, signaling rapid uptake that supports revenue upside and market share gains in the obesity market. Novo’s Wegovy pill tracks over 26,000 prescriptions
• Positive Sentiment: Early sales momentum reinforced by reporting of ~18,000 U.S. prescriptions in week one and commentary that demand is “strong out of the gate,” which supports upside to near‑term sales and investor sentiment. Demand for Novo Nordisk’s Weight Loss Pill Is Strong Out of the Gate. Is the Stock Due for a Big Rally?
• Neutral Sentiment: Analyst view is mixed — one upgrade highlights first‑mover advantage, strong cash and aggressive U.S. marketing but also flags high valuation and potential for near‑term profit‑taking, leading to a cautious “Hold” posture. Novo Nordisk: Momentum Meets Headwinds Before Earnings (Upgrade)
• Neutral Sentiment: Public profile of Novo’s weight‑loss boom is increasing (e.g., a new Danish theatre piece), which is PR‑positive but not directly material to near‑term financials. New play in Denmark charts Novo Nordisk’s weight loss boom
• Negative Sentiment: Leadership change in China: Senior VP and head of China Christine Zhou will step down at end‑of‑March — a potential disruption given China’s importance for growth and ongoing market expansion. Novo Nordisk’s China President Zhou to step down in March
• Negative Sentiment: Near‑term headwinds flagged: analysts warn of slowing Wegovy/Ozempic momentum, pricing pressure and stronger competition that could limit upside to sales growth and margins into the Q4 earnings release. Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock?

Novo Nordisk A/S Stock Up 0.1%

Shares of NVO opened at $59.40 on Friday. The stock has a fifty day moving average of $53.44 and a 200-day moving average of $54.50. The stock has a market capitalization of $265.23 billion, a price-to-earnings ratio of 17.27 and a beta of 0.66. Novo Nordisk A/S has a 52 week low of $43.08 and a 52 week high of $93.80. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.57 and a current ratio of 0.78.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, beating analysts’ consensus estimates of $0.77 by $0.25. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%.The business had revenue of $11.79 billion during the quarter, compared to the consensus estimate of $11.98 billion. As a group, sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on NVO shares. CICC Research initiated coverage on Novo Nordisk A/S in a research note on Friday, January 9th. They issued an “outperform” rating and a $73.50 price target on the stock. Zacks Research upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Friday, January 9th. Jefferies Financial Group assumed coverage on shares of Novo Nordisk A/S in a research report on Monday, October 27th. They issued an “underperform” rating on the stock. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Novo Nordisk A/S in a report on Monday, December 29th. Finally, The Goldman Sachs Group reissued a “buy” rating on shares of Novo Nordisk A/S in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have issued a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $57.79.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.